September 01, 2011
1 min read

10-valent pneumococcal vaccine possible option for premature infants

Omeñaca F. Pediatrics. 2011;doi:10.1542/peds.2010-1184.

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact

The 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine may be an option for premature infants, according to data from Spanish researchers.

Félix Omeñaca, MD, of La Paz Hospital in Madrid, Spain, and colleagues evaluated the safety and immunogenicity of pneumococcal non-typeable H. influenzae protein D conjugate vaccine (PHiD-CV) in 137 preterm infants and compared outcome results with 149 babies born at full gestation.

Three groups of infants received a three-dose primary series at 2, 4 and 6 months of age and a booster dose at 16 to 18 months of age. All of the groups had a similar incidence of solicited general symptoms, with premature infants having generally lower incidences of swelling and redness.

More than 92% of infants in both preterm and term groups reached immunogenicity levels for all of the 10 vaccine pneumococcal serotypes after their primary vaccines, and about 98% reached immunogenicity levels after their booster doses.

“PHiD-CV was well tolerated and immunogenic in preterm infants when given as a three-dose primary vaccination, with robust enzyme-linked immunosorbent assay antibody and [opsonophagocytic activity] booster responses in the second year of life,” the study researchers said. “These results reveal that preterm infants would benefit from PHiD-CV vaccination.”

Disclosure: The researchers received funding from GlaxoSmithKline Biologicals but reported no relevant financial disclosures related to this study.

Twitter Follow the on Twitter.